198 related articles for article (PubMed ID: 22462599)
1. Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma.
Cornelis T; Beckers EA; Driessen AL; van der Sande FM; Koek GH
Clin Toxicol (Phila); 2012 Jun; 50(5):444-5. PubMed ID: 22462599
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
Rosiñol L; Montoto S; Cibeira MT; Bladé J
Arch Intern Med; 2005 Feb; 165(4):464-5. PubMed ID: 15738379
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib and bilateral herpes zoster.
di Meo N; Bergamo S; Dondas A; Trevisan G
Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
[TBL] [Abstract][Full Text] [Related]
4. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
[TBL] [Abstract][Full Text] [Related]
5. Acute pancreatitis caused by bortezomib.
Solakoglu T; Akyol P; Guney T; Dilek I; Atalay R; Koseoglu H; Akin E; Demirezer Bolat A; Buyukasik NS; Ersoy O
Pancreatology; 2013; 13(2):189-90. PubMed ID: 23561979
[TBL] [Abstract][Full Text] [Related]
6. Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
Moon SJ; Min CK; Lee DG; Lee S; Lee JW; Min WS; Kim CC; Kim M; Park G; Kim Y
Acta Haematol; 2007; 117(4):211-4. PubMed ID: 17237615
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.
Perfetti V; Palladini G; Brunetti L; Sgarella A; Brugnatelli S; Gobbi PG; Corazza GR
Eur J Gastroenterol Hepatol; 2007 Jul; 19(7):599-601. PubMed ID: 17556909
[TBL] [Abstract][Full Text] [Related]
8. Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: case report.
Mohiuddin MM; Harmon DC; Delaney TF
J Chemother; 2005 Jun; 17(3):343-6. PubMed ID: 16038531
[TBL] [Abstract][Full Text] [Related]
9. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
10. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Richardson P; Jagannath S; Colson K
Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
12. Breathless on bortezomib.
O'Riordan D; Houghton J; Chisholm R; O'Driscoll BR
BMJ Case Rep; 2011 Aug; 2011():. PubMed ID: 22688931
[TBL] [Abstract][Full Text] [Related]
13. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.
Zappasodi P; Dore R; Castagnola C; Astori C; Varettoni M; Mangiacavalli S; Lazzarino M; Corso A
J Clin Oncol; 2007 Aug; 25(22):3380-1. PubMed ID: 17664489
[No Abstract] [Full Text] [Related]
14. Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
Honton B; Despas F; Dumonteil N; Rouvellat C; Roussel M; Carrie D; Galinier M; Montastruc JL; Pathak A
Fundam Clin Pharmacol; 2014 Jun; 28(3):349-52. PubMed ID: 23781941
[TBL] [Abstract][Full Text] [Related]
15. Expanding role of bortezomib in multiple myeloma: nursing implications.
Colson K; Doss DS; Swift R; Tariman J
Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
Wang HH; Tsui J; Wang XY; Liu SS; Li J
Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
[No Abstract] [Full Text] [Related]
17. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
20. Hyperlipidemia in a myeloma patient after bortezomib treatment.
Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
[No Abstract] [Full Text] [Related]
[Next] [New Search]
